GANX
Gain Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.14 EPS
Last earnings +0.0% on 2026-05-11
$1.75
▲ +1.74%$1.75▼ -1.13%
over 1Y
L $1.44EODHDH $4.18
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.7%
1W-5.4%
1M-1.1%
3M-4.4%
YTD-45.0%
1Y-1.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Conservative balance sheet (liabilities/equity 0.23x); but revenue fell -58.4% YoY.
Gain Therapeutics, Inc. shows $55.2K in FY2023 revenue (-58.4% YoY), a -36537.0% net margin, and -108.6% ROE.
Sources: SEC EDGAR (CIK 0001819411, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 7:06:36 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.